Faron presented more detailed interim results from the BEXMAB study at the ASH conference. The data supports earlier positive findings: 80% of patients achieved a treatment response, with response types predicting longer life expectancy. The life expectancy estimate remained at 13.4 months, but stronger results are expected by the end of Q3 2025. The crucial final report will be released at the end of March 2025, which is also a potential timing for partnership announcements.
Below is a recent analyst report on the company. 